What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2025-02-27 compared with 2024-02-22 · 35 added, 38 removed, 62 unchanged (54% of the section changed)

LEGAL PROCEEDINGS

In June 2023, a putative class action lawsuit was filed against the Company, its Executive Chairman and its Chief Executive Officer.

The complaint, later amended to add our Chief Financial Officer as a defendant, purports to be brought on behalf of a class of persons and/or entities who purchased or otherwise acquired ordinary shares of the Company from January 5, 2023 through June 5, 2023, and alleges material misstatements and/or omissions in the Company’s public statements with respect to the results from its phase 3 LUNAR clinical trial.

In June 2023, a putative class action lawsuit was filed against the Company, its Executive Chairman and its former Chief Executive Officer.

The complaint, later amended to add our former Chief Financial Officer as a defendant, purports to be brought on behalf of a class of persons and/or entities who purchased or otherwise acquired ordinary shares of the Company from January 5, 2023 through June 5, 2023, and alleges material misstatements and/or omissions in the Company’s public statements with respect to the results from its Phase 3 LUNAR clinical trial.

The Company believes that the action is without merit and plans to defend the lawsuit vigorously.

8 unchanged sentences

Name Age Position

Asaf Danziger 57 Chief Executive Officer and Director

Ashley Cordova

46 Chief Executive Officer

William Doyle 62 Executive Chairman and Director

Barak Ben-Arye 49 General Counsel

Ashley Cordova 44 Chief Financial Officer

54 Chief Science Officer

Wilhelmus Groenhuysen 66 Chief Operating Officer

Christoph Brackmann

51 Chief Financial Officer

Francis Leonard 45 Executive Vice President, President Novocure Oncology

Nicholas Leupin

Nicolas Leupin

51 Chief Medical Officer

Mukund Paravasthu

55 Chief Operating Officer

55 Chief Human Resources Officer

Uri Weinberg 47 Chief Innovation Officer

Asaf Danziger has served as our Chief Executive Officer since 2002 and has been a director of NovoCure since 2012.

From 1998 to 2002, Mr.

Danziger was CEO of Cybro Medical, a subsidiary of Imagyn Medical Technologies, Inc.

Danziger holds a B.Sc.

in material engineering from Ben Gurion University of the Negev, Israel.

Ashley Cordova has been our Chief Executive Officer since January 1, 2025.

From September 2020 to December 2024, Ms.

Cordova served as our Chief Financial Officer and from October 2018 to August 2020, she served as our Senior Vice President, Finance and Investor Relations.

Cordova joined us in June 2014 as Director of Global Treasury.

In March 2015, she became our Senior Director, Investor Relations and Global Treasury, and in July 2016, she became our Vice President, Finance and Investor Relations.

Prior to joining us, Ms.

Cordova served in various financial roles at Zoetis Inc.

from 2012 to 2014 and Pfizer Inc.

from 2005 to 2012.

Cordova graduated with a bachelor’s degree in Music and Business from Furman University, and earned her International Master of Business Administration from the University of South Carolina.

William Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.

1 unchanged sentence

Prior to 2002, Mr.

Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and Acquisitions.

Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and

Acquisitions.

While at Johnson & Johnson, Mr.

4 unchanged sentences

Doyle is also a member of the Governing Board of the Pershing Square Sohn Cancer Research Alliance.

From 2014 to 2016 he was a member of the investment team at Pershing Square Capital Management L.P., a private investment firm and from November 2016 to January 2021, Mr.Doyle served as the Executive

Chairman of BlinkHealth LLC, which has developed a pharmacy-as-a-service, e-commerce platform.

From 2014 to 2016 he was a member of the investment team at Pershing Square Capital Management L.P., a private investment firm and from November 2016 to January 2021, Mr.Doyle served as the Executive Chairman of BlinkHealth LLC, which has developed a pharmacy-as-a-service, e-commerce platform.

Doyle has been a director of Elanco Animal Health, Inc.

9 unchanged sentences

Ben-Arye earned his Bachelor of Laws and his Bachelor of Business Administration from Reichman University (IDC Herzliya) in Israel.

Ashley Cordova has been our Chief Financial Officer since September 2020.

From October 2018 to August 2020, Ms.

Cordova served as our Senior Vice President, Finance and Investor Relations.

Cordova joined us in June 2014 as Director of Global Treasury.

In March 2015, she became our Senior Director, Investor Relations and Global Treasury, and in July 2016, she became our Vice President, Finance and Investor Relations.

Prior to joining us, Ms.

Cordova served in various financial roles at Zoetis Inc.

from 2012 to 2014 and Pfizer Inc.

from 2005 to 2012.

Cordova graduated with a bachelor’s degree in Music and Business from Furman University, and earned her International Master of Business Administration from the University of South Carolina.

Moshe Giladi, Ph.D., has been our Chief Science Officer since July 2023.

Giladi joined Novocure in 2005 and most recently held the title of Senior Vice President of Preclinical Research.

He holds a Ph.D.

in Microbiology and Biochemistry and a master’s degree in business administration from Tel Aviv University.

Wilhelmus Groenhuysen has been our Chief Operations Officer since September 2020 and prior to that was our Chief Financial Officer since 2012.

He has served on the Board of Optinose Inc., a commercial-stage specialty pharmaceuticals company, since October 2017.

From 2007 to 2011, Mr.

Groenhuysen worked for Cephalon, Inc., a U.S.

biopharmaceutical company, last serving as executive vice president and chief financial officer, where he had responsibility for worldwide finance, commercial operations and risk management.

From 1987 to 2007, Mr.

Groenhuysen worked for Philips Group in various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to chief financial officer and senior vice president of Philips Electronics North America Corporation.

Groenhuysen holds a Master’s Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.

Christoph Brackmann has been our Chief Financial Officer since January 1, 2025.

Brackmann joined us as a Special Advisor to the Chief Financial Officer in October 2024.

Prior to joining Novocure, Mr.

Brackmann served as the Senior Vice President of Finance at Moderna Inc.

from October 2019 to June 2024.

Brackmann earned his Master of Business Administration from the SDA Bocconi School of Management, Milan in 2003 and holds a bachelors degree in Business and Economics from the University of Mannheim.

Frank Leonard has been our Executive Vice President, President Novocure Oncology since January 2024.

5 unchanged sentences

from the London School of Economics and Political Science.

Nicholas Leupin, M.D., Ph.D., has served as our Chief Medical Officer since January 2024.

Nicolas Leupin, M.D., Ph.D., has served as our Chief Medical Officer since January 2024.

Leupin previously served as Chief Medical Officer of Molecular Partners AG since August 2019.

5 unchanged sentences

from the Université Bourgogne-Franche-Comté.

Mukund Paravasthu has been our Chief Operating Officer since October 2024.

Paravasthu previously served as Novocure’s Senior Vice President of Product Development beginning in April 2022.

Paravasthu joined us in May 2020 as Vice President of Product Development.

Before joining Novocure, Mr.

Paravasthu held several leadership roles at Johnson & Johnson’s orthopedic franchise, DePuy Synthes, from 2007.

Paravasthu holds a Master’s degree in Electrical Engineering from the University of Oklahoma and a Bachelors in Electrical and Electronics Engineering from Annamalai University, India.

Michael Puri has served as our Chief Human Resources Officer since September 2023.

10 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings